Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYN-010 in IBS-C
NCT03763175Phase 2Terminated
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Dec 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SYN-010 in irritable bowel syndrome (IBS) (3 arms), sponsored by Cedars-Sinai Medical Center. Primary endpoint: Change From Baseline in the Weekly Average Number of Completely Spontaneous Bowel Movements at 12 weeks. Started Dec 2018; status: terminated.
02
Drugs
SYN-010
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT03763175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03763175.